文献速递乳腺癌

早期ERBB2/HER2阳性乳腺癌的肿瘤内在亚型与基因表达特征:CALGB 40601、NeoALTTO和NSABP B-41试验的汇总分析

Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
PubMed 文献 · JAMA Oncol · 2024-01-01

该回顾性汇总分析纳入3项3期试验共1289例早期ERBB2/HER2阳性乳腺癌患者,接受化疗联合曲妥珠单抗、拉帕替尼或两者联合,中位随访5.5年,对758例样本行RNA测序。pCR与EFS的关联因内在亚型而异,双靶向获益限于ERBB2富集型。

要点

  • pCR与EFS的关联在ERBB2富集型(HR 0.45)和基底样型(HR 0.19)显著,在luminal A或B型不显著。
  • ERBB2富集型中曲妥珠单抗加拉帕替尼较曲妥珠单抗单药显著改善EFS(HR 0.47)。
  • 618个基因表达特征中275个(44.5%)与pCR显著相关,9个(1.5%)与EFS显著相关。

核心结论

  • 在早期ERBB2/HER2阳性乳腺癌中,pCR与EFS的关联因肿瘤内在亚型而异,双靶向ERBB2/HER2阻断的获益限于ERBB2富集型肿瘤。
  • 免疫激活特征一致地与较高pCR率和较好EFS相关,而luminal特征与较低pCR率相关。

研究设计与样本

  • 回顾性汇总分析,纳入CALGB 40601、NeoALTTO和NSABP B-41三项3期试验共1289例早期ERBB2/HER2阳性乳腺癌患者,接受化疗联合曲妥珠单抗、拉帕替尼或两者联合,合并中位随访5.5年。
  • 对758例样本行RNA测序基因表达谱分析,计算内在亚型和618个基因表达特征;数据分析时间为2020年6月1日至2023年1月1日。

主要发现

  • 在758例女性中,中位年龄49岁,12%为亚洲人,6%为黑人,75%为白人。
  • pCR与EFS的关联在ERBB2富集型(HR 0.45;95%CI 0.29-0.70;P<.001)和基底样型(HR 0.19;95%CI 0.04-0.86;P=.03)显著,在luminal A或B型不显著。
  • 在意向治疗人群中,曲妥珠单抗加拉帕替尼对比曲妥珠单抗单药有EFS获益趋势;但在ERBB2富集型中,曲妥珠单抗加拉帕替尼对比曲妥珠单抗单药有显著且独立的EFS获益(HR 0.47;95%CI 0.27-0.83;P=.009)。
  • 618个基因表达特征中,275个(44.5%)与pCR显著相关,9个(1.5%)与EFS显著相关;ERBB2/HER2扩增子和多个免疫特征与pCR显著相关。
  • luminal相关特征与较低pCR率但较好EFS相关,尤其在残留病灶患者中且独立于激素受体状态;pCR的校正HR范围为0.45至0.81(较高pCR)和1.21至1.94(较低pCR率),EFS的校正HR范围为0.71至0.94。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Biologic features may affect pathologic complete response (pCR) and event-free survival (EFS) after neoadjuvant chemotherapy plus ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer (EBC). OBJECTIVE: To define the quantitative association between pCR and EFS by intrinsic subtype and by other gene expression signatures in a pooled analysis of 3 phase 3 trials: CALGB 40601, NeoALTTO, and NSABP B-41. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective pooled analysis, 1289 patients with EBC received chemotherapy plus either trastuzumab, lapatinib, or the combination, with a combined median follow-up of 5.5 years. Gene expression profiling by RNA sequencing was obtained from 758 samples, and intrinsic subtypes and 618 gene expression signatures were calculated. Data analyses were performed from June 1, 2020, to January 1, 2023. MAIN OUTCOMES AND MEASURES: The association of clinical variables and gene expression biomarkers with pCR and EFS were studied by logistic regression and Cox analyses. RESULTS: In the pooled analysis, of 758 women, median age was 49 years, 12% were Asian, 6% Black, and 75% were White. Overall, pCR results were associated with EFS in the ERBB2-enriched (hazard ratio [HR], 0.45; 95% CI, 0.29-0.70; P < .001) and basal-like (HR, 0.19; 95% CI, 0.04-0.86; P = .03) subtypes but not in luminal A or B tumors. Dual trastuzumab plus lapatinib blockade over trastuzumab alone had a trend toward EFS benefit in the intention-to-treat population; however, in the ERBB2-enriched subtype there was a significant and independent EFS benefit of trastuzumab plus lapatinib vs trastuzumab alone (HR, 0.47; 95% CI, 0.27-0.83; P = .009). Overall, 275 of 618 gene expression signatures (44.5%) were significantly associated with pCR and 9 of 618 (1.5%) with EFS. The ERBB2/HER2 amplicon and multiple immune signatures were significantly associated with pCR. Luminal-related signatures were associated with lower pCR rates but better EFS, especially among patients with residual disease and independent of hormone receptor status. There was significant adjusted HR for pCR ranging from 0.45 to 0.81 (higher pCR) and 1.21-1.94 (lower pCR rate); significant adjusted HR for EFS ranged from 0.71 to 0.94. CONCLUSIONS AND RELEVANCE: In patients with ERBB2/HER2-positive EBC, the association between pCR and EFS differed by tumor intrinsic subtype, and the benefit of dual ERBB2/HER2 blockade was limited to ERBB2-enriched tumors. Immune-activated signatures were concordantly associated with higher pCR rates and better EFS, whereas luminal signatures were associated with lower pCR rates.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Fernandez-Martinez A, Rediti M, Tang G, et al. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. JAMA Oncol. 2024. PMID: 38546612. doi:10.1001/jamaoncol.2023.7304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。